Literature DB >> 6143668

The metabolic effects of dopamine in man.

A Pernet, V A Hammond, G Blesa-Malpica, J Burrin, H Orskov, K G Alberti, D G Johnston.   

Abstract

The metabolic effects of dopamine have been investigated by its infusion in normal man with and without simultaneous somatostatin administration. Dopamine was infused into overnight fasted men at 1.5 microgram/kg/min (n = 6) and 3.0 micrograms/kg/min (n = 5) for 120 min. Plasma dopamine concentrations at 120 min were 78 +/- 9 nmol/l and 117 +/- 17 nmol/l respectively, associated with a marginal rise in plasma noradrenaline. Dopamine (1.5 microgram/kg/min) induced an early and sustained rise in plasma glucagon (48 +/- 9 pg/ml versus 19 +/- 6 pg/ml in saline controls at 10 min, p less than 0.01) and a transient elevation in serum growth hormone which peaked to 17.7 (range 4.5-71.8) mU/l at 60 min (7.2 (range 0.6-37.7) mU/l with saline, p less than 0.05) but did not alter serum insulin, blood glucose or other metabolite levels. At 3.0 micrograms/kg/min, dopamine in addition provoked mild and transient elevations in blood glucose and serum insulin. Somatostatin (250 micrograms/h) suppressed circulating insulin, glucagon, and growth hormone levels and abolished the small hyperglycaemic effect seen with the higher dopamine dose. Somatostatin alone induced a progressive rise in circulating non-esterified fatty acid and 3-hydroxybutyrate levels reflecting insulin deficiency. This rise in NEFA and 3-hydroxybutyrate was increased by dopamine particularly at the higher dosage (plasma NEFA; somatostatin alone, 1.08 +/- 0.13 mmol/l; somatostatin plus dopamine 3 micrograms/kg/min, 1.44 +/- 0.17 mmol/l at 120 min, p less than 0.01: blood 3-hydroxybutyrate; somatostatin alone, 0.32 +/- 0.04 mmol/l; somatostatin plus dopamine 3 micrograms/kg/min, 0.56 +/- 0.12 mmol/l at 120 min, p less than 0.05). Thus: 1) dopamine at pharmacological dosage has minor effects when other endocrine mechanisms are intact, 2) it enhances lipolysis and ketogenesis during somatostatin-induced insulin deficiency; 3) the hyperglycaemia effect of the higher dopamine dose is probably mediated through stimulated glucagon secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6143668     DOI: 10.1007/bf00546703

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  A sensitive double antibody radioimmunoassay for human growth hormone (HGH): levels of serum HGH following rapid tolbutamide infusion.

Authors:  G Boden; J S Soeldner
Journal:  Diabetologia       Date:  1967-10       Impact factor: 10.122

2.  Critical variables in the radioimmunoassay of serum insulin using the double antibody technic.

Authors:  J S Soeldner; D Slone
Journal:  Diabetes       Date:  1965-12       Impact factor: 9.461

3.  Free and conjugated plasma and urinary dopamine in human hypertension.

Authors:  O Kuchel; N T Buu; T Unger; M Lis; J Genest
Journal:  J Clin Endocrinol Metab       Date:  1979-03       Impact factor: 5.958

4.  Plasma dopamine responses to standing and exercise in man.

Authors:  G R Van Loon; L Schwartz; M J Sole
Journal:  Life Sci       Date:  1979-06-11       Impact factor: 5.037

5.  Dopamine during alpha- or beta-adrenergic blockade in man. Hormonal, metabolic, and cardiovascular effects.

Authors:  M Lorenzi; J H Karam; E Tsalikian; N V Bohannon; J E Gerich; P H Forsham
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

6.  Metabolic effects of acute and prolonged growth hormone excess in normal and insulin-deficient man.

Authors:  P Metcalfe; D G Johnston; R Nosadini; H Orksov; K G Alberti
Journal:  Diabetologia       Date:  1981-02       Impact factor: 10.122

7.  Plasma and urinary dopamine: studies during fasting and exercise and in tetraplegic man.

Authors:  N J Christensen; C J Mathias; H L Frankel
Journal:  Eur J Clin Invest       Date:  1976-09-10       Impact factor: 4.686

Review 8.  Dopamine (3-hydroxytyramine) and brain function.

Authors:  O Hornykiewicz
Journal:  Pharmacol Rev       Date:  1966-06       Impact factor: 25.468

9.  Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man.

Authors:  D Robertson; G A Johnson; R M Robertson; A S Nies; D G Shand; J A Oates
Journal:  Circulation       Date:  1979-04       Impact factor: 29.690

10.  Dopaminergic control of ketogenesis in fasting.

Authors:  G Blesa-Malpica; D G Johnston; J M Burrin; H Orskov; A B Heath; K G Alberti
Journal:  Clin Endocrinol (Oxf)       Date:  1981-05       Impact factor: 3.478

View more
  3 in total

Review 1.  Dopaminergic Pathways in Obesity-Associated Inflammation.

Authors:  Fernanda Leite; Laura Ribeiro
Journal:  J Neuroimmune Pharmacol       Date:  2019-07-17       Impact factor: 4.147

2.  Dose-dependent separation of dopaminergic and adrenergic effects of epinine in healthy volunteers.

Authors:  A Daul; M Elter-Schulz; U Poller; F Jockenhövel; K Pönicke; F Boomsma; A J Man in't Veld; R F Schäfes; O E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

3.  The effects of dopamine infusion on the postoperative energy expenditure, metabolism, and catecholamine levels of patients after esophagectomy.

Authors:  M Nakagawa; Y Shinozawa; N Ando; N Aikawa; M Kitajima
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.